Strontium ranelate effect on bone bone mineral density is modified by previous bisphosphonate treatment.

BRUN LR; GALICH AM; MAFFEI L; PREMROU V; VEGA E; SALERNI H; SARLI MA; COSTANZO P; REY P; LARROUDÉ MS; MOGGIA MS; BRANCE ML; SÁNCHEZ A

Baltimore, Maryland

Congreso; American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2013; 2013

American Society for Bone and Mineral Research (ASBMR)

Strontium ranelate (SrR) is an effective treatment for osteoporosis that reduces the incidence of vertebral and non-vertebral fractures. The aim of this study was to evaluate the effect of SrR on bone mineral density (BMD) and bone turnover markers after 1 year of treatment in clinical practice conditions. Additionally, the effect of SrR in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study analyzed records from 482 postmenopausal women treated with SrR (2 g/day) for 1 year in eleven Argentine centers; 41 patients were excluded due to insufficient data, while 441 were included. All patients received calcium (1000 mg/day) and vitamin D (800 U/day). BMD (g/cm2) was measured by dual-energy X-ray absorptiometry (DXA) GE Lunar Prodigy. Data are expressed as mean±SEM, and changes were analyzed with Mann-Whitney test or Wilcoxon signed rank test as appropriate. Results: the whole population main characteristics were: age (years): 67.20±0.50; body mass index (kg/m2): 24.55±0.18; serum calcium (mg/dl): 9.36±0.02; serum phosphate (mg/dl): 3.97±0.03; 25(OH)vitamin D (ng/ml): 32.04±1.0; PTH (pg/ml): 51.00±3.11; total alkaline phosphatase (tAP, UI/L): 59.70±1.36; serum osteocalcin (BGP, ng/ml): 17.02±0.98; serum C-telopeptide (s-CTX, ng/l): 331.10±16.03. After 1 year of treatment with SrR, tAP (65.76±1.57) and BGP (22.93±1.46) as bone formation markers, were increased (p